ImmunityBio, Inc. IBRX Allowance for Doubtful Accounts Receivable (Current)
Allowance for Doubtful Accounts Receivable (Current) at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
During the three months ended March 31, 2026 and 2025, approximately $8.5 million and $3.2 million, respectively, of gross-to-net adjustments have been recorded as a reduction of revenue on the condensed consolidated statements of operations. As of March 31, 2026 and December 31, 2025, approximately $2.5 million and $2.0 million, respectively, of allowances for prompt payment discounts, product returns and chargebacks were included in accounts receivable, net, and approximately $8.1 million and $6.3 million, respectively, related to accrued rebates, co-payment assistance and other fees were included in accrued expenses and other liabilities, on the condensed consolidated balance sheets.
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s allowance for doubtful accounts receivable (current)?
- ImmunityBio, Inc. (IBRX) reported allowance for doubtful accounts receivable (current) of $2.5M in Q1 2026.
- How has ImmunityBio, Inc.'s allowance for doubtful accounts receivable (current) changed year-over-year?
- ImmunityBio, Inc.'s allowance for doubtful accounts receivable (current) increased by 525.0% year-over-year, from $400K to $2.5M.
- What does allowance for doubtful accounts receivable (current) mean?
- This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.
Ask your AI about ImmunityBio, Inc.'s allowance for doubtful accounts receivable (current).
Connect your AI assistant and compare it to peers, right in your chat.
